Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

C7744

Sigma-Aldrich

Combretastatin A4

≥98% (HPLC), powder

Sinonimo/i:

1-(3,4,5-Trimethoxyphenyl)-2-(3′-hydroxy-4′-methoxyphenyl) ethane 3,4,5-trimethoxy-3′-hydroxy-4′-methoxystilbene, 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, CA4

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
111,00 €
25 MG
459,00 €

111,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
5 MG
111,00 €
25 MG
459,00 €

About This Item

Formula empirica (notazione di Hill):
C18H20O5
Numero CAS:
Peso molecolare:
316.35
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

111,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

powder

Colore

off-white

Solubilità

DMSO: >10 mg/mL

Temperatura di conservazione

−20°C

Stringa SMILE

COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O

InChI

1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-
HVXBOLULGPECHP-WAYWQWQTSA-N

Descrizione generale

Combretastatin A4 belong to the class of colchicinoids compounds.[1]

Applicazioni

Combretastatin A4 has been used:
  • as an anti-tubulin agent to determine the effects of isocitrate dehydrogenases (IDH1 and IDH2) proteins in G2/M phase[2]
  • to evaluate the anti-proliferative and pro-apoptotic properties of biphenyl CA4 derivatives in both 2D and 3D cancerous and non-cancerous cell models[1]
  • as a microtubule inhibitor to study its effects on motility of Ascaris suum L3 larvae[3]

Azioni biochim/fisiol

Combretastatin A4 is a potent microtubule targeting agent (MTA).[1]
Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis.
Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol.

Pittogrammi

Skull and crossbonesCorrosion

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 2

1 of 2

Paclitaxel from semisynthetic, ≥98%

Sigma-Aldrich

T7191

Paclitaxel

Colchicina BioReagent, suitable for plant cell culture, ≥95% (HPLC)

Sigma-Aldrich

C3915

Colchicina

Thomas Nielsen et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(23), 6469-6477 (2012-10-17)
Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clinical trials. As CA4P acts on dividing endothelial cells, we hypothesize that CA4P affects vessels of certain sizes. The aim of this study was to evaluate the
Eric Y Huang et al.
Journal of cellular and molecular medicine, 22(7), 3661-3670 (2018-04-24)
Single nucleotide polymorphisms (SNPs) within the regulatory elements of a gene can alter gene expression, making these SNPs of prime importance for candidate gene association studies. We aimed to determine whether such regulatory variants are associated with clinical outcomes in
S Papiol et al.
Translational psychiatry, 7(6), e1159-e1159 (2017-06-28)
Preliminary studies suggest that, besides improving cognition, aerobic exercise might increase hippocampal volume in schizophrenia patients; however, results are not consistent. Individual mechanisms of volume changes are unknown but might be connected to the load of risk genes. Genome-wide association
B Cao et al.
Molecular psychiatry, 22(9), 1352-1358 (2017-01-25)
Volume reduction and shape abnormality of the hippocampus have been associated with mood disorders. However, the hippocampus is not a uniform structure and consists of several subfields, such as the cornu ammonis (CA) subfields CA1-4, the dentate gyrus (DG) including
Lisa M Greene et al.
Biochemical pharmacology, 84(5), 612-624 (2012-06-19)
Recent clinical data demonstrated that the vascular targeting agent Combretastatin-A4 phosphate (CA-4P) prolonged survival of patients with advanced anaplastic thyroid cancer without any adverse side effects. However, as a single agent CA-4 failed to reduce tumour growth in the murine

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.